What We Offer

Nuraxs is an AI-powered scientific advancement platform that transforms pharmaceutical R&D by combining machine learning with real lab validation. We’re starting with thermal stability optimization (our wedge) – where pharmaceutical and biotech companies can waste upward of $250,000 per failed study and expanding to transform all R&D workflows that haven’t changed in decades. We offer comprehensive workflow, not just software.

  • AI Prediction: Edge temperatures where Arrhenius kinetics fail

  • Lab Validation: Partner lab validates predictions with multi-temperature kinetics (2-3 weeks)

  • Patent-Pending Advanced Analysis: Curvature and R^2 algorithms detect subtle breakdown patterns

  • Protocol Development: Custom stress study and HPLC method conditions for each compound

  • Regulatory Report: ICH-compliant documentation ready for FDA submissions

This isn’t just another software-only tool

We are building the first platform that grounds AI prediction in real lab data, creating a defensible moat through:

  • Partnership with Valentia Analytical (GMP/GLP Lab, ISO17025:2017 Accredited, AOAC Accredited, FDA Registered)
  • Growing dataset of gold-standard validated thermal edges
  • 79% proven efficiency gain in HPLC method development (600+ chromatograms validated)

Today’s pharma tools haven’t changed in decades – Y Combinator’s Diana Hu notes that these legacy approaches need AI disruption. We are that disruption: transforming how physical medicines are developed with AI and lab validation, not just software predictions.

Patent-Pending: (U.S. 63/846,863, July 2025). Production-ready. 3 pharma pilots pending.